Treatment News : Preliminary Estimate Says PrEP Takes 7 Days to Work

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » May 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

May 29, 2014

Preliminary Estimate Says PrEP Takes 7 Days to Work

Truvada (emtricitabine/tenofovir) as pre-exposure prophylaxis (PrEP) against HIV takes an estimated seven days to reach full efficacy and may protect for nearly a week afterward, the National AIDS Treatment Advocacy Project (NATAP) reports. But those taking PrEP should not assume these are hard facts at this time. Presenting their findings at the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy in Washington, DC, researchers conducted an analysis of 11 men and 10 women who took daily Truvada as PrEP for 30 days and then, after stopping the drug, remained in an additional 30 days of follow-up.

The researchers collected peripheral blood mononuclear cells (PBMCs) on the participants’ first day of Truvada treatment as well as on days 3, 7, 20 and 30 of treatment, and then they collected samples 5, 15 and 30 days after the participants stopped the drug. The investigators also took rectal biopsies of the participants in order to collect mononuclear cells.

After seven days of treatment, a total of 87.6 percent of the participants reached the blood level of Truvada that the iPrEX study calculated was necessary to reduce the risk of contracting HIV by 90 percent. Eighty-six percent saw the blood level of the drug stay at this concentration for two days after stopping treatment.

The researchers calculated a 99 percent risk reduction for contracting HIV seven days after beginning Truvada, as well as a 95 percent risk reduction for six days after ending treatment.

The researchers caution that these findings are preliminary and this is far from the last word on the matter. Anyone who advises people on PrEP should not tell them that the seven-day time to full efficacy and the six-day tail period of efficacy apply to all.

To read the NATAP report, click here.

Search: Pre-exposure prophylaxis, PrEP, emtricitabine, tenofovir, National AIDS Treatment Advocacy Project, NATAP, Truvada.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.